SHINEWAY PHARM (02877) declined over 2% in afternoon trading, dropping 2.14% to HKD 8.69 by the time of writing, with a turnover of HKD 5.3445 million. The company announced during the midday break that its unaudited management accounts for the nine months ended September 30, 2025, showed revenue of RMB 2.415 billion, down 16.3% year-on-year.

Breakdown of the revenue decline includes: - Injectable products revenue fell 23.6% to RMB 786 million. - Soft capsule products revenue dropped 13.7% to RMB 337 million. - Granule products revenue decreased 14.5% to RMB 391 million. - Traditional Chinese medicine formula granule products revenue declined 11.8% to RMB 726 million. - Other dosage forms revenue slipped 6.1% to RMB 175 million.